Fresenius Medical Care AG & Co. (FMS)
(Real Time Quote from BATS)
$22.09 USD
+0.11 (0.50%)
Updated Nov 22, 2024 12:18 PM ET
2-Buy of 5 2
A Value C Growth F Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FMS 22.09 +0.11(0.50%)
Will FMS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FMS
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now?
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View
Other News for FMS
Fresenius Medical price target raised to EUR 41 from EUR 39 at Barclays
Fresenius Medical price target raised by EUR 2 at Barclays
Fresenius Medical’s Novalung ECMO System selected by Premier
Fresenius Medical's Novalung ECMO System selected by Premier
Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA